This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Maki Ishii: Innovator in Peptide Agonist Discovery
Introduction
Maki Ishii is a prominent inventor based in Kyoto, Japan. She has made significant contributions to the field of peptide ligand discovery, particularly in developing methods for identifying agonists for membrane-bound receptors. Her innovative work has implications for various applications in biochemistry and pharmacology.
Latest Patents
Maki Ishii holds a patent for a "Method for discovery of peptide agonists." This invention focuses on a detection system that utilizes a 'tethered' ligand to probe receptor binding. The system comprises a membrane, a membrane-bound receptor, and a chimeric ligand presenting molecule. The chimeric protein forms the tethered ligand and includes a membrane domain, a linker domain, a ligand domain, and a cleavable terminal domain. The ligands are exposed through the addition of a specific peptidase that cleaves at a designated sequence. The resulting interaction between the agonist and receptor allows for the isolation of the ligand sequence that produces a signal.
Career Highlights
Maki Ishii is affiliated with the University of California, where she continues her research and development in the field of peptide discovery. Her work has garnered attention for its innovative approach and potential applications in drug development.
Collaborations
Maki has collaborated with notable colleagues, including Shaun R. Coughlin and Ji Chen, enhancing her research through shared expertise and insights.
Conclusion
Maki Ishii's contributions to peptide agonist discovery exemplify the intersection of innovation and scientific research. Her patented methods pave the way for advancements in understanding receptor interactions and developing new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
